Psychiatry
Social Anxiety Disorder
47
Pipeline Programs↗
7
Active Trials↗
27
Companies Involved↗
Social Anxiety Disorder is a moderately active landscape with 47 programs across 27 companies. The most active players are Retrophin, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., UCB. 14 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 19
Phase 216
Phase 37
Analysis
Trial Status
55
clinical trials
Completed40 · 73%
Recruiting5 · 9%
Withdrawn3 · 5%
Terminated3 · 5%
Unknown status2 · 4%
Active, not recruiting2 · 4%
Clinical Trials
Trial Activity
55 trials
Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder
Recruiting·—·Phase 4·NCT07192367·56 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)